Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published Date:

Abstract

PURPOSE: With the increased use of focal radiation dose escalation for primary prostate cancer (PCa), accurate delineation of gross tumor volume (GTV) in prostate-specific membrane antigen PET (PSMA-PET) becomes crucial. Manual approaches are time-consuming and observer dependent. The purpose of this study was to create a deep learning model for the accurate delineation of the intraprostatic GTV in PSMA-PET.

Authors

  • Julius C Holzschuh
    Department of Radiation Oncology, Medical Center - University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany; Faculty of Computer Science, Karlsruhe Institute of Technology, Karlsruhe, Germany. Electronic address: julius.holzschuh@uniklinik-freiburg.de.
  • Michael Mix
    Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Juri Ruf
    Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Tobias Hölscher
    Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
  • Jörg Kotzerke
    German Cancer Consortium, Heidelberg, Germany.
  • Alexis Vrachimis
    Department of Nuclear Medicine, German Oncology Center - University Hospital of the European University, Limassol, Cyprus.
  • Paul Doolan
    Department of Radiation Oncology, German Oncology Center - University Hospital of the European University, Limassol, Cyprus.
  • Harun Ilhan
    Department of Nuclear Medicine, University Hospital - Ludwig-Maximilians-Universität, Munich, Germany.
  • Ioana M Marinescu
    Department of Radiation Oncology, Medical Center - University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.
  • Simon K B Spohn
    Department of Radiation Oncology, Medical Center - University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany; Faculty of Medicine - University of Freiburg, Berta-Ottenstein-Programme, Freiburg, Germany.
  • Tobias Fechter
    Division of Medical Physics, Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Dejan Kuhn
    Department of Radiation Oncology, Medical Center - University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany; Division of Medical Physics, Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
  • Peter Bronsert
    Tumorbank Comprehensive Cancer Center Freiburg and Center for Surgical Pathology, Medical Center - University of Freiburg, Faculty of Medicine, Breisacher Straße 115a, Freiburg i. Br., 79106, Germany.
  • Christian Gratzke
    Department of Urology, LMU Munich, Munich, Germany. Electronic address: christian.gratzke@med.uni-muenchen.de.
  • Radu Grosu
    Cyber-Physical Systems Division, Institute of Computer Engineering and Faculty of Informatics, Technical University of Vienna, Vienna, Austria; Department of Computer Science, State University of New York at Stony Brook, NY, USA.
  • Sophia C Kamran
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Pedram Heidari
    Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Wht 427, Boston, MA 02114, USA. Electronic address: pheidari@mgh.harvard.edu.
  • Thomas S C Ng
    Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
  • Arda Konik
    Dana-Farber Cancer Institute Department of Radiation Oncology, Boston, MA, USA.
  • Anca-Ligia Grosu
    German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.
  • Constantinos Zamboglou
    German Cancer Consortium (DKTK), Partner Site Freiburg, Germany constantinos.zamboglou@uniklinik-freiburg.de.